<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roussos, S.</style></author><author><style face="normal" font="default" size="100%">Protopapas, K</style></author><author><style face="normal" font="default" size="100%">Mastrogianni, E.</style></author><author><style face="normal" font="default" size="100%">Totsikas, C.</style></author><author><style face="normal" font="default" size="100%">Moschopoulos, C. D.</style></author><author><style face="normal" font="default" size="100%">Bourmpoutelis, S.</style></author><author><style face="normal" font="default" size="100%">Resta, P.</style></author><author><style face="normal" font="default" size="100%">Procter, K.</style></author><author><style face="normal" font="default" size="100%">Kokolesis, E.</style></author><author><style face="normal" font="default" size="100%">Antoniadou, A</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Papastamopoulos, V</style></author><author><style face="normal" font="default" size="100%">Beloukas, A.</style></author><author><style face="normal" font="default" size="100%">Katsarolis, I</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author><author><style face="normal" font="default" size="100%">Psichogiou, M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Rapid ART Initiation with BIC/FTC/TAF in People Who Inject Drugs in Greece: Results from a Pilot Single-Arm Study of an Integrated Care Model</style></title><secondary-title><style face="normal" font="default" size="100%">Microorganism</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Microorganisms</style></alt-title><short-title><style face="normal" font="default" size="100%">MicroorganismsMicroorganisms</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">and a research grant from Gilead Sciences for this</style></keyword><keyword><style  face="normal" font="default" size="100%">and advisory boards, and support for participation in congresses from Gilead</style></keyword><keyword><style  face="normal" font="default" size="100%">and Biotest. V.P. has received honoraria and consultation fees from Gilead</style></keyword><keyword><style  face="normal" font="default" size="100%">and consulting fees from Gilead</style></keyword><keyword><style  face="normal" font="default" size="100%">and equipment, materials, drugs, or services from</style></keyword><keyword><style  face="normal" font="default" size="100%">attending meetings and/or travel from Gilead Sciences and GSK (paid to the</style></keyword><keyword><style  face="normal" font="default" size="100%">authors declare that the research was conducted in the absence of any commercial</style></keyword><keyword><style  face="normal" font="default" size="100%">bictegravir/emtricitabine/tenofovir alafenamide</style></keyword><keyword><style  face="normal" font="default" size="100%">Cepheid, including free-of-charge reagents for a research project, all outside</style></keyword><keyword><style  face="normal" font="default" size="100%">company Gilead Sciences Hellas (Medical Affairs Department). The remaining</style></keyword><keyword><style  face="normal" font="default" size="100%">Department). V.S. has received grants from Gilead Sciences and Roche</style></keyword><keyword><style  face="normal" font="default" size="100%">fees from Gilead Sciences, GSK, and MSD</style></keyword><keyword><style  face="normal" font="default" size="100%">for lectures from Gilead Sciences and Roche</style></keyword><keyword><style  face="normal" font="default" size="100%">from Gilead Sciences. A.A. has received a research grant, honoraria for lectures</style></keyword><keyword><style  face="normal" font="default" size="100%">Gilead Sciences and GSK (paid to the University of West Attica)</style></keyword><keyword><style  face="normal" font="default" size="100%">grant and sponsorship to the University of West Attica) and GSK (research</style></keyword><keyword><style  face="normal" font="default" size="100%">honoraria</style></keyword><keyword><style  face="normal" font="default" size="100%">honoraria (speaker fees) and travel support for medical and scientific events</style></keyword><keyword><style  face="normal" font="default" size="100%">honoraria for lectures,</style></keyword><keyword><style  face="normal" font="default" size="100%">integrated care model</style></keyword><keyword><style  face="normal" font="default" size="100%">interest. The authors declare that this study received funding from Gilead</style></keyword><keyword><style  face="normal" font="default" size="100%">involved in the collection, analysis and interpretation of data or the decision</style></keyword><keyword><style  face="normal" font="default" size="100%">opioid agonist therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">or financial relationships that could be construed as a potential conflict of</style></keyword><keyword><style  face="normal" font="default" size="100%">patient-reported outcomes</style></keyword><keyword><style  face="normal" font="default" size="100%">peer navigation</style></keyword><keyword><style  face="normal" font="default" size="100%">people who inject drugs</style></keyword><keyword><style  face="normal" font="default" size="100%">presentations, speakers’ bureaus, manuscript writing, or educational events from</style></keyword><keyword><style  face="normal" font="default" size="100%">rapid ART initiation</style></keyword><keyword><style  face="normal" font="default" size="100%">representative of the study sponsor. M.P. has received honoraria and consultation</style></keyword><keyword><style  face="normal" font="default" size="100%">retention in care</style></keyword><keyword><style  face="normal" font="default" size="100%">Sciences (collaborative study CO-GR-380-6083). The funder contributed to the</style></keyword><keyword><style  face="normal" font="default" size="100%">Sciences and honoraria for lectures and advisory boards from Pfizer, AstraZeneca,</style></keyword><keyword><style  face="normal" font="default" size="100%">Sciences, with payments made to an affiliated institution. A.H. has served as a</style></keyword><keyword><style  face="normal" font="default" size="100%">Sciences. A.B. has received grants and contracts from Gilead Sciences (research</style></keyword><keyword><style  face="normal" font="default" size="100%">sponsorship to the University of West Attica)</style></keyword><keyword><style  face="normal" font="default" size="100%">study design and the drafting/review of the manuscript. The funder was not</style></keyword><keyword><style  face="normal" font="default" size="100%">support for</style></keyword><keyword><style  face="normal" font="default" size="100%">support for attending meetings and/or</style></keyword><keyword><style  face="normal" font="default" size="100%">the submitted work. I.K. is an employee of Gilead Sciences (Medical Affairs</style></keyword><keyword><style  face="normal" font="default" size="100%">to submit it for publication.</style></keyword><keyword><style  face="normal" font="default" size="100%">travel from Gilead Sciences</style></keyword><keyword><style  face="normal" font="default" size="100%">University of West Attica)</style></keyword><keyword><style  face="normal" font="default" size="100%">work as principal investigator. Author Ioannis Katsarolis is employed by the</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Nov 26</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/12/31</style></edition><volume><style face="normal" font="default" size="100%">13</style></volume><isbn><style face="normal" font="default" size="100%">2076-2607 (Print)2076-2607</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">People who inject drugs (PWIDs) remain underserved in HIV care. Evidence on rapid antiretroviral therapy (ART) for PWID is limited. We evaluated feasibility, effectiveness, safety, and patient-reported outcomes (PROs) for rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) supported by a peer navigation in Greece. This is a single-arm, multicenter pilot study including PWIDs (≥18 years) newly diagnosed or relinking after &amp;gt;3 months off ART. Participants started BIC/FTC/TAF on the same day or within 7 days and received peer navigation for 48 weeks. Co-primary endpoints were Week-24 virologic suppression (HIV-1 RNA &amp;lt; 50 copies/mL; FDA Snapshot) and grade 3-4 adverse events (AEs). Secondary endpoints included complete-case suppression at Weeks 24/48, CD4 recovery, retention, and PROs. Outcomes were compared with historical controls from the same centers. Thirty-seven participants were enrolled (83.8% male; median age 33.3 years). Median time to ART was 0 days (vs 78 in controls, p &amp;lt; 0.001). Retention was 67.6% at Week 24 and 54.1% at Week 48. In the primary (FDA Snapshot) analysis, suppression was 62.2% and 54.1% at Weeks 24 and 48; in complete-case analyses, results were 92.0% and 100%, respectively. Mean CD4 count increased by 208 cells/μL (95% CI 141-275) at Week 48. Quality of life improved and symptom burden decreased. No grade 3-4 AEs occurred. Rapid BIC/FTC/TAF with peer navigation eliminated delays to ART and achieved favorable virologic, immunologic, and PROs among those retained, with good tolerability. Despite retention challenges, this model appears feasible for PWID and may help close HIV care gaps toward UNAIDS 95-95-95 targets.</style></abstract><accession-num><style face="normal" font="default" size="100%">41471901</style></accession-num><notes><style face="normal" font="default" size="100%">2076-2607Roussos, SotiriosOrcid: 0000-0003-2347-0817Protopapas, KonstantinosOrcid: 0000-0001-5404-746xMastrogianni, ElpidaOrcid: 0000-0003-3081-9415Totsikas, CharisisOrcid: 0009-0008-7179-2742Moschopoulos, Charalampos DOrcid: 0000-0001-9954-7409Bourmpoutelis, StylianosResta, PanagiotaProcter, KassandraOrcid: 0009-0004-5413-3287Kokolesis, EvangelosAntoniadou, AnastasiaOrcid: 0000-0003-0991-9198Papadopoulos, AntoniosOrcid: 0000-0003-4735-2620Papastamopoulos, VasileiosOrcid: 0000-0001-6293-0017Beloukas, ApostolosOrcid: 0000-0001-5639-0528Katsarolis, IoannisOrcid: 0000-0002-5710-1545Sypsa, VanaOrcid: 0000-0002-9430-7614Hatzakis, AngelosOrcid: 0000-0001-8420-3830Psichogiou, MinaOrcid: 0000-0002-3000-8447Not available now/Gilead/Journal ArticleSwitzerlandMicroorganisms. 2025 Nov 26;13(12):2697. doi: 10.3390/microorganisms13122697.</style></notes><custom2><style face="normal" font="default" size="100%">PMC12735862</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Chaidari, Greece.1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.5th Department of Internal Medicine-Infectious Diseases Unit, Evangelismos General Hospital, 10676 Athens, Greece.Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.National AIDS Reference Centre of Southern Greece, School of Public Health, University of West Attica, 12243 Athens, Greece.Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, 11475 Athens, Greece.Medical Affairs, Gilead Sciences Hellas, 17564 Paleo Faliro, Greece.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>